Lyra Therapeutics Faces Nasdaq Delisting Notice
Ticker: LYRA · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: LYRA
TL;DR
Nasdaq's coming for Lyra's listing, but they got 180 days to fix it.
AI Summary
Lyra Therapeutics, Inc. announced on July 19, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has 180 days to regain compliance, with a potential extension.
Why It Matters
This notice signals potential financial distress or operational challenges for Lyra Therapeutics, which could impact its stock value and ability to raise capital.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major exchange like Nasdaq indicates significant non-compliance with listing standards, posing a substantial risk to the company's market presence and investor confidence.
Key Numbers
- 180 days — Compliance Period (Time Lyra has to regain compliance with Nasdaq listing rules.)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing notice
- July 19, 2024 (date) — Date of notice
FAQ
What specific Nasdaq listing rule(s) did Lyra Therapeutics fail to meet?
The filing states Lyra received a notice indicating non-compliance with Nasdaq's listing standards, but does not specify which particular rule(s) were violated.
What is the deadline for Lyra Therapeutics to regain compliance?
Lyra Therapeutics has 180 days from the date of the notice, July 19, 2024, to regain compliance with the Nasdaq listing standards.
Can Lyra Therapeutics appeal the delisting notice?
The filing does not explicitly mention an appeal process, but typically companies have the right to appeal such notices from Nasdaq.
What are the potential consequences if Lyra Therapeutics fails to regain compliance?
If Lyra Therapeutics fails to regain compliance within the specified period, its securities may be delisted from the Nasdaq Stock Market.
Has Lyra Therapeutics previously received such notices?
This filing does not provide historical information about previous delisting notices received by Lyra Therapeutics.
Filing Stats: 1,095 words · 4 min read · ~4 pages · Grade level 15.5 · Accepted 2024-07-23 16:05:32
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
- $1.00 — e "Common Stock"), had closed below the $1.00 per share minimum bid price requirement
Filing Documents
- d871197d8k.htm (8-K) — 26KB
- 0001193125-24-182860.txt ( ) — 147KB
- lyra-20240719.xsd (EX-101.SCH) — 3KB
- lyra-20240719_lab.xml (EX-101.LAB) — 18KB
- lyra-20240719_pre.xml (EX-101.PRE) — 11KB
- d871197d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: July 23, 2024 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer